公开(公告)号：US20240402176A1

公开(公告)日：2024-12-05

申请号：US18696817

申请日：2022-09-29

Applicant: RANDOX LABORATORIES LTD.

Inventor： Stephen Peter Fitzgerald ,  Mark Ruddock ,  John Lamont

IPC: G01N33/574 ,  G01N33/543

Abstract: Haematuria is a considerable burden within primary and secondary care; too many haematuria patients are referred to secondary care for invasive and expensive investigations that could be managed in primary care. The current invention has identified biomarker combinations with utility for the diagnosis of bladder cancer in males. Using gender specific biomarker algorithms in combination with clinical risks that are associated with bladder cancer, would allow clinicians to better manage haematuria patients in primary care setting.

公开(公告)号：US20240345092A1

公开(公告)日：2024-10-17

申请号：US18682668

申请日：2022-08-10

Applicant: RANDOX LABORATORIES LTD.

Inventor： Stephen Peter Fitzgerald ,  Mark Ruddock ,  John Lamont ,  Declan McKenna

IPC: G01N33/574

CPC classification number: G01N33/57434 ,  G01N33/57488

Abstract: Single markers lack both sensitivity and specificity to stratify risk of PCa in patients who present with elevated tPSA and abnormal DRE. The novel combination of serum markers identified in this study could be employed to help triage patients into ‘low’ and ‘high’ risk categories, allowing general practitioners (GPs) to improve management of patients in primary care settings and potentially reducing the number of referrals for unnecessary, invasive, and costly treatments.

公开(公告)号：US11467163B2

公开(公告)日：2022-10-11

申请号：US16065646

申请日：2016-12-23

Applicant: Randox Laboratories Ltd. ,  Randox Teoranta

Inventor： Ivan McConnell ,  Peter Fitzgerald ,  John Lamont ,  Ciaran Richardson

IPC: G01N33/574

Abstract: The present invention describes methods of determining the glycosylation signature and determining the level of a protein in a sample obtained from a patient.
The present invention also describes use of a patient protein glycosylation profile to identify the presence or absence of a disease in subjects.

公开(公告)号：US11383216B2

公开(公告)日：2022-07-12

申请号：US16424330

申请日：2019-05-28

Applicant: Randox Laboratories Ltd. ,  Randox Teoranta

Inventor： Peter Fitzgerald ,  John Lamont ,  Ivan McConnell ,  Elouard Benchikh ,  Deepesh Upadhyay ,  Ciaran Richardson

IPC: B01J19/00 ,  C09D11/102 ,  C09D11/03 ,  G01N33/543 ,  C12M1/00

Abstract: A substrate comprising a coating of a masking material, and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached, wherein said zones are uncoated areas on the substrate.

公开(公告)号：US20190293662A1

公开(公告)日：2019-09-26

申请号：US16462924

申请日：2017-11-23

Applicant: Randox Laboratories Ltd ,  Randox Teoranta

Inventor： Ciaran Richardson ,  Ivan McConnell ,  John Lamont ,  Stephen Peter Fitzgerald

IPC: G01N33/68 ,  C07K16/18

Abstract: Described are methods and kits for diagnosing stroke using GFAP derivatives.

公开(公告)号：US10168331B2

公开(公告)日：2019-01-01

申请号：US15304473

申请日：2015-04-02

Applicant: Randox Laboratories Ltd.

Inventor： Mark Ruddock ,  Cherith Reid ,  John Lamont ,  Stephen Fitzgerald ,  Ricardo De Matos Simoes ,  Kathleen Williamson

IPC: G01N33/574 ,  G01N33/68 ,  G01N33/543 ,  G01N33/577

Abstract: The present invention provides a method and a solid state device for identifying the presence of urothelial cancer in a patient comprising assigning the subject to a sub-population according to smoking habits, measuring the level of each biomarker of a panel of biomarkers in one or more samples obtained from the subject; and correlating the measured levels of the panel of biomarkers with the likelihood of the subject having urothelial cancer such that the subject can be classified as having urothelial cancer or as being a control.

公开(公告)号：US20230406933A1

公开(公告)日：2023-12-21

申请号：US18035070

申请日：2021-11-02

Applicant: Randox Laboratories Ltd.

Inventor： Marshall Dunlop ,  Shirley Schon ,  John Lamont ,  Peter Fitzgerald

IPC: C07K16/28

CPC classification number: C07K16/2827 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/33 ,  C07K2317/22 ,  C07K2317/94 ,  C07K2317/76

Abstract: The present invention relates to therapeutic antibodies, or antigen-binding portions thereof, for use in the treatment of cancer and infectious disease. Specifically, the present invention relates to therapeutic antibodies, or antigen-binding portions thereof, that target the programmed death-ligand 1 polypeptide. The present invention also relates to pharmaceutical compositions comprising said therapeutic antibody, or antigen-binding portions thereof.

公开(公告)号：US20220412994A1

公开(公告)日：2022-12-29

申请号：US17775217

申请日：2020-11-06

Applicant: Randox Laboratories Ltd

Inventor： Paul Innocenzi ,  Mark Ruddock ,  John Lamont ,  Peter Fitzgerald

IPC: G01N33/68

Abstract: Described is the use of GFAP as a marker of drug-induced cellular toxicity and depression.

公开(公告)号：USD815752S1

公开(公告)日：2018-04-17

申请号：US29510481

申请日：2014-11-28

Applicant: Randox Laboratories Ltd.

Designer： Stuart Jackson ,  Ivan McConnell ,  John Lamont ,  Peter Fitzgerald

公开(公告)号：US20180011115A1

公开(公告)日：2018-01-11

申请号：US15547608

申请日：2016-01-29

Applicant: Randox Laboratories Ltd.

Inventor： Mark W. Ruddock ,  Cherith N. Reid ,  Kate E. Williamson ,  John Lamont ,  Peter Fitzgerald

IPC: G01N33/86

CPC classification number: G01N33/86 ,  G01N33/57407 ,  G01N33/6893 ,  G01N2800/50 ,  G01N2800/709

Abstract: The present invention related to a method for detecting a history of exposure to a chemical(s) comprising measuring the concentration of thrombomodulin in a sample isolated from a subject, and determining whether the concentration of thrombomodulin is altered compared to control reference levels.